- Conditions
- HIV Infections, Kidney Diseases
- Interventions
- Maraviroc, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV Infection
- Interventions
- Maraviroc, Emtricitabine, Tenofovir disoproxil fumarate, Maraviroc placebo, Emtricitabine placebo, Tenofovir disoproxil fumarate placebo
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 594 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- HIV Infections
- Interventions
- Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG), Maraviroc (MVC)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 23
- States / cities
- Los Angeles, California • San Diego, California • Torrance, California + 19 more
- Conditions
- HIV-1 Infection
- Interventions
- FTC/TDF, F/TAF, Allowed third antiretroviral agent, FTC/TDF Placebo, F/TAF Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 668 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 57
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more
- Conditions
- HIV-1 Infection
- Interventions
- F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 567 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 34
- States / cities
- Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
- Conditions
- Long COVID
- Interventions
- Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
- Drug
- Lead sponsor
- HealthBio, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- HIV-1 Infection
- Interventions
- Darunavir, Ritonavir, Tenofovir disoproxil fumarate, Emtricitabine, Placebo for Tenofovir disoproxil fumarate, Placebo for Maraviroc, Maraviroc
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 262 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 26 more